Please login to the form below
epigenetics
This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.
MorphoSys expands oncology pipeline with $1.7bn acquisition of Constellation Pharmaceuticals
German biopharma company MorphoSys has announced that it will acquire Constellations Pharmaceuticals, a clinical-stage company with expertise in epigenetics, for a total of $1.7bn. ... We are proud that MorphoSys has recognised the strength of our team,
Latest news
-
UK scientists begin testing BCG vaccine for severe COVID-19 protection
In the same article, the authors added that the BCG vaccine induces metabolic and epigenetic changes that enhance innate immune response to subsequent infections in a process called ‘trained immunity’.
-
BMS’ oral maintenance therapy boosts survival in AML patients
We are extremely encouraged by the results of the QUAZAR AML-001 study as a part of our continuing commitment to both epigenetic research and myeloid diseases,” said Samit Hariwat, chief
-
RNA-focused biotech Storm Therapeutics raises extra £14m
First set up in 2015 by epigenetics and RNA specialists Professor Tony Kouzarides and Professor Eric Miska, the Cambridge-based company has a pipeline of early-stage molecules in development in ... world-leading company harnessing the power of RNA
-
Researchers reverse Alzheimer’s memory loss in mice
The Buffalo researchers believe their work in the developing science of epigenetics will yield answers in the elusive search for new Alzheimer's therapies. ... The researchers found that the loss of glutamate receptors resulted from an epigenetic process
-
GSK: we won’t be splitting up any time soon
Particularly in the spotlight is oncology, where GSK has cell therapy candidates, epigenetic modulators and antibodies targeting immune cells.
UK scientists begin testing BCG vaccine for severe COVID-19 protection
BMS’ oral maintenance therapy boosts survival in AML patients
RNA-focused biotech Storm Therapeutics raises extra £14m
Researchers reverse Alzheimer’s memory loss in mice
GSK: we won’t be splitting up any time soon
More from news
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
The expansion of Alzheimer’s R&D is underpinned by evidence that the disease has a range of drivers, including Abeta, inflammation and epigenetics, that evolve as it progresses. ... And a host of other academic and industry teams are looking at
-
Deal Watch November 2016
licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.
-
Deal Watch January 2016
Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research
-
Deal Watch October 2015
Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).
-
Pharma deals in August 2015
This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.
Where next in Alzheimer’s disease R&D?
Deal Watch November 2016
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
ICR appoints Kristian Helin as its new chief executive
Epigenetics Research.
-
Professor Thomas Cech joins Storm Therapeutics
mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.
-
Storm Therapeutics bolsters its team
As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,
-
Storm Therapeutics strengthens its board
RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.
-
Rubius Therapeutics strengthens senior team
He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing
ICR appoints Kristian Helin as its new chief executive
Professor Thomas Cech joins Storm Therapeutics
Storm Therapeutics bolsters its team
Storm Therapeutics strengthens its board
Rubius Therapeutics strengthens senior team
More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Embattled Biogen talks up Aduhelm
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- New data from Moderna supports COVID boosters
- $47.5m research centre to seek genetic insights into disease
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Nicky Hutchens appointed as deputy managing director at Four Health
- Health For All
- Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- David Hunt launches independent agency The Considered
- bluebird bio gears up for split
- Ashfield Health announces three new senior hires
- The new reality of building a corporate brand in pharma
- EU “still interested” in Valneva COVID vaccine despite UK snub
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
- How to pick the perfect training program for your healthcare professionals
- You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...
